Efficacy of vonoprazan fumarate in treatment of patients with chronic atrophic gastritis
Objective To explore the efficacy and safety of vonoprazan fumarate in the treatment of chronic atrophic gastritis(CAG).Methods According to random number table method,100 patients with Helicobacter pylori(HP)positive CAG admitted to Jinhua Hospital of Traditional Chinese Medicine from February 2021 to April 2023 were divided into the control group and observation group,with 50 in each group.All the patients in both groups were given light diet.Meanwhile,they were asked to avoid spicy and acidic food,smoking and alcohol and using of gastric mucosa-irritating drugs.The patients in both groups were treated with antibiotics amoxicillin capsules,clarithromycin tablets,and gastric mucosal protector colloidal bismuth pectin capsules.In addition,the patients in control group were treated with traditional proton pump inhibitor omeprazole enteric coated capsules,while the patients in observation group were treated with a new proton pump inhibitor,vorolazone fumarate tablets.Clinical efficacy and adverse event profiles were compared between the two groups.Results The observation group exhibited a significantly higher total clinical effective rate of 98.00%(49/50)than that of 76.00%(38/50)in the control group(χ2=10.698,P=0.001).The Helicobacter pylori eradication rate was also markedly higher in the observation group at 90.00%(45/50)than that of 74.00%(37/50)in the control group(χ2=4.336,P=0.037).The levels of PG Ⅰ and PG Ⅰ/PG Ⅱ after treatment were significantly increased(all P<0.05)while the levels of PG Ⅱ significantly decreased in both groups(both P<0.05).After treatment,the levels of PG Ⅰ and PG Ⅰ/PG Ⅱ in the observation group were higher than those in the control group(PGⅠ:(6.91±1.58)ng·mL-1 vs(5.43±1.91)ng·mL-1;PG Ⅰ/PG Ⅱ:(6.91±1.58)vs(5.43±1.91))(t=4.115,4.222,both P<0.05),and the levels of PGⅡ were significantly lower than those in the control group(P<0.05).After treatment,the serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-8(IL-8)in the two groups were lower than before treatment,and the levels of TNF-α,IL-6,and IL-8 in the observation group were lower than those in the control group after treatment(all P<0.05).The incidence of adverse reactions was not statistically different between the two groups(P>0.05).Conclusion Vonoprazan fumarate can improve the gastrointestinal mucosal function of patients with chronic atrophic gastritis,enhance the level of gastric motility and help to cure HP infection.It has anti-inflammatory effect,significant clinical efficacy and good safety.Therefore,it is worthy of promotion.
NETL
NSTL
万方数据
